DCC4668 |
Sdz Ser 082 Fumarate |
Selective 5-HT2B/2C receptor antagonist |
|
DCC4669 |
sdz-285604 |
Novel inhibitor of sterol 14a-demethylases (CYP51) |
|
DCC4670 |
Sdz-lap-977 |
Potent antiproliferative agent, binding to the “colchicine binding site” on tubulin and inhibiting tubulin polymerization in vitro |
|
DCC4671 |
sdz-nkt343 |
Highly selective human tachykinin NK1 receptor antagonist |
|
DCC4672 |
Secologanate |
Natural plant growth inhibitor |
|
DCC4673 |
Seco-rapamycin Ethyl Ester |
Novel open-ring metabolite of rapamycin derivative |
|
DCC4674 |
Securinine Mononitrate |
Antagonist of gamma-aminobutyric acid A (GABA A ) receptor and cholinergic agent |
|
DCC4675 |
Seh/ache Inhibitor 12c |
Novel Highly Potent Dual Inhibitor of Soluble Epoxide Hydrolase and Acetylcholinesterase for the Treatment of Alzheimer's Disease |
|
DCC4676 |
Seh-in-12 |
Novel potent inhibitor of the enzyme soluble epoxide hydrolase (sEH) |
|
DCC4677 |
Sempai |
Novel AkaLumine analog, acting asa NIR emission luciferin with the enhanced solubility in water |
|
DCC4678 |
Sen205a |
Novel S100B inhibitor |
|
DCC4679 |
Sen461 |
Novel Wnt inhibitor/Axin stabilizer |
|
DCC4680 |
Sen-826 |
Novel potent antagonist of the Hedgehog pathway |
|
DCC4681 |
Senp1-in-8e |
Sentrin-specific protease 1 (SENP1) inhibitor |
|
DCC4682 |
Se-nsaid-8 |
Novel selenium-nonsteroidal anti-inflammatory drug (Se-NSAID), inhibiting colorectal cancer (CRC) growth via the inhibition of the cell cycle in G1 and G2/M phases and reduces the cell cycle markers like cyclin E1 and B1 in a dose dependent manner |
|
DCC4683 |
Sephin1 Hydrochloride |
Selective inhibitor of the phosphatase regulatory subunit PPP1R15A (R15A) that prolong the benefit of eIF2α phosphorylation, thereby protecting cells from proteostatic defects |
|
DCC4684 |
Ser@tpp@cur |
Novel mitochondrial KIM-1 receptor modulator to be specifically internalized by renal tubular epithelial cells via KIM-1 receptor-mediated endocytosis and then actively distributed in mitochondria under the effect of TPP, effectively ameliorating injured |
|
DCC4685 |
Sert Inhibitor 69419 |
Novel serotonin reuptake inhibitor |
|
DCC4686 |
Sertaconazole |
Cytochrome P450 14α-demethylase inhibitor, also acting as a BuChE-IDO1 inhibitor |
|
DCC4687 |
Setastine |
Highly selective H1 receptor antagonist |
|
DCC4688 |
Sethrrs Inhibitor 36j |
The first-in-class triple-site aaRS inhibitor, targeting Salmonella enterica threonyl-tRNA synthetase (SeThrRS) with IC 50 = 19 nM and K d = 35.4 nM |
|
DCC4689 |
Setin-1 |
The most potent inhibitor of Set7, inhibiting the KMTase G9a |
|
DCC4690 |
Trichomonacid |
Novel inhibitor of Mycobacterium marinum MelF (Rv1936), exhibiting bacteriostatic/bactericidal activity against M. marinum and M. tuberculosis in vitro |
|
DCC4691 |
Seviteronel |
Novel potent CYP17 lyase inhibitor, inhibiting androgen production without mineralocorticoid excess or cortisol depletion |
|
DCC4692 |
sew05920 |
Novel telomerase inhibitor |
|
DCC4693 |
Sew-05929 |
The First potent SecA inhibitor |
|
DCC4694 |
Sf-1-087 |
Potent and selective STAT5 inhibitor |
|
DCC4695 |
Sf-22 (npy Y2 Antagonist) |
Potent, selective, and highly brain-penetrant NPY Y2 receptor antagonist |
|
DCC4696 |
Sf2535 |
Novel dual inhibitor of BRD4 and PI3K, inhibiting BRD4, PI3Kα, PI3Kδ, and PI3Kγ with IC 50 values of 277, 714, 27, and 1170 nM, respectively |
|
DCC4697 |
Sfom-0046 |
Novel anticancer agent, arresting cell cycle in S-phase and causes DNA replication stress leading to the phosphorylation of H2AX into gamma-H2AX |
|